We are live on ! Find out more
BBOT

BridgeBio Oncology
BBOT

31 hedge funds and large institutions have $171M invested in BridgeBio Oncology in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

2% more capital invested

Capital invested by funds: $167M → $171M (+$3.69M)

0% more funds holding

Funds holding: 31 → 31 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

2.44% less ownership

Funds ownership: 89.02% → 86.59% (-2.4%)

Holders
31
Holders Change
–
Holders Change %
0%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SSA
Schonfeld Strategic Advisors
New York
+$1.24M
2
SCM
Silverarc Capital Management
Massachusetts
+$138K
3
Millennium Management
Millennium Management
New York
+$134K
4
ACP
Acuta Capital Partners
California
+$32.2K
5
Citadel Advisors
Citadel Advisors
Florida
+$1.47K

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$949K
2
Walleye Trading
Walleye Trading
New York
-$534K
3
CAC
Cowen and Company
New York
-$56.5K
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$31.8K
5
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$24.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$30.4M – – –
BlackRock
2
BlackRock
New York
$15.7M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$14.6M – – –
Citadel Advisors
4
Citadel Advisors
Florida
$13.9M +$1.47K +142 +0%
Millennium Management
5
Millennium Management
New York
$11.8M +$134K +12,917 +1%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$11.8M -$31.8K -3,079 -0.3%
SC
7
Sculptor Capital
New York
$7.37M – – –
FCM
8
Farallon Capital Management
California
$6.27M – – –
SCM
9
Silverarc Capital Management
Massachusetts
$5.36M +$138K +13,369 +3%
CC
10
Commodore Capital
New York
$5.22M – – –
GPP
11
Great Point Partners
Connecticut
$5.22M – – –
PA
12
Perceptive Advisors
New York
$5.22M – – –
SFM
13
Soros Fund Management
New York
$4.96M – – –
ACM
14
ADAR1 Capital Management
Texas
$4.22M – – –
T. Rowe Price Investment Management
15
T. Rowe Price Investment Management
Maryland
$4.16M -$24.3K -2,351 -0.6%
LCM
16
Laurion Capital Management
New York
$3.13M – – –
GTC
17
Ghost Tree Capital
New York
$3.13M – – –
AAA
18
Affinity Asset Advisors
New York
$2.61M – – –
OCA
19
Octagon Capital Advisors
New York
$2.61M – – –
SC
20
Stempoint Capital
New York
$2.09M – – –
Two Sigma Investments
21
Two Sigma Investments
New York
$1.98M – – –
Wellington Management Group
22
Wellington Management Group
Massachusetts
$1.93M – – –
ACP
23
Acuta Capital Partners
California
$1.89M +$32.2K +3,109 +2%
TD Asset Management
24
TD Asset Management
Ontario, Canada
$1.51M – – –
SSA
25
Schonfeld Strategic Advisors
New York
$1.25M +$1.24M +119,880 New
1
2

BBOT Hedge Fund Activity: Q3 2024 in Review

31 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q3 2024, worth a combined $171M — up 2.2% from $167M a quarter earlier.

Fund positioning in BBOT was balanced in Q3 2024: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 3 trimmed.

The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $1.24M. The largest seller was Walleye Capital, exiting entirely with an estimated $949K sold.

  • 31 institutional investors held BridgeBio Oncology (BBOT) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $171M of BridgeBio Oncology stock for Q3 2024, up 2.2% quarter-over-quarter.
  • 2 funds opened new BridgeBio Oncology positions in Q3 2024 and 2 closed out, a net change of 0 holders.
  • The largest BridgeBio Oncology buyer in Q3 2024 was Schonfeld Strategic Advisors, an estimated $1.24M added.
  • The largest BridgeBio Oncology seller in Q3 2024 was Walleye Capital, an estimated $949K sold.

Based on aggregated 13F filings for Q3 2024.